Shingles Vaccine Market to Reach USD 12.53 Billion by 2032, Growing at a CAGR of 12.68%
Straits Research is excited to present its latest findings on the rapidly expanding shingles vaccine market. Valued at USD 4.28 billion in 2023, the market is projected to grow from USD 4.82 billion in 2024 to an impressive USD 12.53 billion by 2032, at a compound annual growth rate (CAGR) of 12.68% during the forecast period from 2024 to 2032. The growing elderly population, along with increasing awareness about the benefits of shingles vaccination, are key factors driving this robust market growth.
Market Definition
A shingles vaccine is a medical solution designed to protect individuals from shingles, a painful condition caused by the reactivation of the varicella-zoster virus. The vaccines work by boosting the immune response to prevent the virus from reactivating. These vaccines have proven to be particularly effective in older adults, who are at a higher risk of developing shingles. The shingles vaccine market comprises various products, including recombinant and live attenuated vaccines, each offering distinct benefits and protection.
For a detailed analysis and to access a full PDF sample of the report, visit this link.
Market Dynamics
Key Trends:
- Increased Awareness and Health Campaigns: Public health initiatives and awareness campaigns by governments and health organizations are significantly influencing the growth of the shingles vaccine market. The growing knowledge about the effectiveness of the vaccine in preventing shingles and its complications, such as postherpetic neuralgia, is encouraging higher vaccine uptake.
- Technological Advancements in Vaccine Development: The development of more effective and safe vaccines, including recombinant vaccine formulations, is a major trend driving the market. These innovations offer enhanced immunity with fewer side effects compared to older vaccine types.
Market Drivers:
- Rising Incidence of Shingles Among Older Adults: The global aging population is one of the primary drivers of the shingles vaccine market. As individuals age, the risk of reactivating the varicella-zoster virus increases, making vaccination a critical preventive measure for older adults.
- Government Recommendations for Vaccination: The increasing endorsement of shingles vaccination by healthcare authorities and governments worldwide is propelling the market. Many countries now recommend shingles vaccination for individuals aged 50 and above, which is further boosting vaccine adoption.
Market Opportunities:
- Expansion in Emerging Markets: As healthcare infrastructure improves in emerging regions, there is a growing opportunity for the shingles vaccine market. Countries in Asia Pacific, Latin America, and Africa are expected to see a rise in vaccine adoption as healthcare access increases.
- Investment in R&D for Enhanced Vaccines: Ongoing research and development into next-generation vaccines are presenting opportunities for manufacturers to bring advanced formulations to market. These new vaccines could address gaps in immunity and offer longer-lasting protection.
Market Segmentation
The shingles vaccine market is segmented based on product type and vaccine type, as outlined below:
By Product:
- Shingrix
- Zostavax
- SKYZoster
By Vaccine Type:
- Recombinant Vaccine
- Live Attenuated Vaccine
For a detailed segmentation breakdown, access the full report at this link.
Key Players in the Market
The shingles vaccine market is dominated by several key players involved in the development and distribution of vaccines worldwide. These companies include:
- Merck & Co., Inc.
- GlaxoSmithKline plc
- SK Bioscience
- Green Cross Corp
- Geneone Life Science
- Vaccitech
- CanSinoBIO
- Cipla Inc.
- Pfizer Inc.
- Curevo Inc.
- SK chemicals
- GSK plc
- CanSino Biologics Inc
- GeneOne Life Science Inc.
- Green Cross Corp
Regional Insights
North America currently dominates the shingles vaccine market due to a well-established healthcare infrastructure, high vaccine acceptance rates, and a significant aging population. However, the Asia Pacific region is expected to be the fastest-growing market during the forecast period. Factors contributing to this growth include rising healthcare spending, increasing awareness of shingles vaccination, and the expanding elderly population in countries such as China, Japan, and India.
Conclusion
The shingles vaccine market is set for substantial growth, with projections indicating that it will reach USD 12.53 billion by 2032. The market is driven by an aging global population, increasing awareness of vaccine benefits, and government-backed vaccination programs. With a CAGR of 12.68%, the shingles vaccine market is poised to witness significant advancements and expanding opportunities over the next decade.
For more information, inquiries, or custom reports, visit this link.
This press release highlights the key trends, drivers, and opportunities that are shaping the future of the shingles vaccine market. With the advancement of vaccine technologies and the growing demand for shingles prevention, the market is well-positioned for ongoing success.
